EMMAC Life Sciences Group brings together cutting-edge scientific research with the latest innovations in medical cannabis cultivation, extraction and production.
SEED first invested in European medical cannabis company EMMAC in March 2019 to the tune of £2m.
Between 2019-2021, we provided financial and advisory support to its team including the participation in a Convertible Loan Note (‘CLN’) at a cash cost of £750k. In April 2021, we sold our entire interest to Curaleaf Holdings Inc., a leading medical and wellness cannabis operator in the US, for c. £5m cash recording a profit on the sale of approximately £1.9m, to deliver an overall return of 1.86 times our original investment. The proceeds of this sale were then used to make further investments in accordance with our investing policy.